Biochanin A reduces pancreatic cancer survival and progression

Anti-Cancer Drugs

Volumn 25, Issue 3, 2014, Pages 296-302

  Bhardwaj, Vikas ^a   Tadinada, Satya Murthy ^b   Jain, Aditi ^c   Sehdev, Vikas ^d   Daniels, Christopher K ^e   Lai, James C K ^e   Bhushan, Alok ^f  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d LONG ISLAND UNIVERSITY   (United States)

^e IDAHO STATE UNIVERSITY   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Biochanin A; Epidermal growth factor receptor; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENISTEIN; HUMANS; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84895075927     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000044     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Moore PS, Beghelli S, Zamboni G, Scarpa A. Genetic abnormalities in pancreatic cancer. Mol Cancer 2003; 2: 1-6.
3. Fryer RA, Galustian C, Dalgleish AG. Recent advances and developments in treatment strategies against pancreatic cancer. Curr Clin Pharmacol 2009; 4: 102-112.
4. Zalatnai A, Molnar J. Review. Molecular background of chemoresistance in pancreatic cancer. In Vivo 2007; 21: 339-347.
5. Rosenberg L. Pancreatic cancer: a review of emerging therapies. Drugs 2000; 59: 1071-1089.
6. Zalatnai A. Pancreatic cancer - a continuing challenge in oncology. Pathol Oncol Res 2003; 9: 252-263.
7. Boyle P, Hsieh CC, Maisonneuve P, La Vecchia C, Macfarlane GJ, Walker AM, et al. Epidemiology of pancreas cancer. Int J Pancreatol 1989; 5: 327-346.
8. Wenzel U, Kuntz S, Brendel MD, Daniel H. Dietary flavone is a potent apoptosis inducer in human colon carcinoma cells. Cancer Res 2000; 60: 3823-3831.
9. Baghurst PA, McMichael AJ, Slavotinek AH, Baghurst KI, Boyle P, Walker AM. A case-control study of diet and cancer of the pancreas. Am J Epidemiol 1991; 134: 167-179.
10. Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 2006; 20: 197-209.
11. Banerjee S, Li Y, Wang Z, Sarkar FH. Multi-targeted therapy of cancer by genistein. Cancer Lett 2008; 269: 226-242.
12. Taylor CK, Levy RM, Elliott JC, Burnett BP. The effect of genistein aglycone on cancer and cancer risk: a review of in vitro, preclinical, and clinical studies. Nutr Rev 2009; 67: 398-415.
13. Snyder RD, Gillies PJ. Evaluation of the clastogenic, DNA intercalative, and topoisomerase II-interactive properties of bioflavonoids in Chinese hamster V79 cells. Environ Mol Mutagen 2002; 40: 266-276.
14. Sehdev V, Lai JC, Bhushan A. Biochanin A modulates cell viability, invasion, and growth promoting signaling pathways in HER-2-positive breast cancer cells. J Oncol 2009; 2009: 1-10.
15. Johnson TL, Lai MB, Lai JC, Bhushan A. Inhibition of cell proliferation and MAP kinase and Akt pathways in oral squamous cell carcinoma by genistein and biochanin A. Evid Based Complement Alternat Med 2010; 7: 351-358.
16. Puli S, Lai JC, Bhushan A. Inhibition of matrix degrading enzymes and invasion in human glioblastoma (U87MG) cells by isoflavones. J Neurooncol 2006; 79: 135-142.
17. Saif MW, Karapanagiotou L, Syrigos K. Genetic alterations in pancreatic cancer. World J Gastroenterol 2007; 13: 4423-4430.
18. Abraham JA, Damm D, Bajardi A, Miller J, Klagsbrun M, Ezekowitz RA. Heparin-binding EGF-like growth factor: characterization of rat and mouse cDNA clones, protein domain conservation across species, and transcript expression in tissues. Biochem Biophys Res Commun 1993; 190: 125-133.
19. Shing Y, Christofori G, Hanahan D, Ono Y, Sasada R, Igarashi K, et al. Betacellulin: a mitogen from pancreatic beta cell tumors. Science 1993; 259: 1604-1607.
20. Funatomi H, Itakura J, Ishiwata T, Pastan I, Thompson SA, Johnson GR, et al. Amphiregulin antisense oligonucleotide inhibits the growth of T3M4 human pancreatic cancer cells and sensitizes the cells to EGF receptor-targeted therapy. Int J Cancer 1997; 72: 512-517.
21. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993; 13: 565-569.
22. Bhardwaj V, Rizvi N, Lai MB, Lai JC, Bhushan A. Glycolytic enzyme inhibitors affect pancreatic cancer survival by modulating its signaling and energetics. Anticancer Res 2010; 30: 743-749.
23. Rothmeier AS, Schneiders UM, Wiedmann RM, Ischenko I, Bruns CJ, Rudy A, et al. The marine compound spongistatin 1 targets pancreatic tumor progression and metastasis. Int J Cancer 2010; 127: 1096-1105.
24. Mahato R, Qin B, Cheng K. Blocking IKKalpha expression inhibits prostate cancer invasiveness. Pharm Res 2011; 28: 1357-1369.
25. Holcomb B, Yip-Schneider MT, Matos JM, Dixon J, Kennard J, Mahomed J, et al. Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies. J Gastrointest Surg 2008; 12: 288-296.
26. Silverman DT, Swanson CA, Gridley G, Wacholder S, Greenberg RS, Brown LM, et al. Dietary and nutritional factors and pancreatic cancer: a case-control study based on direct interviews. J Natl Cancer Inst 1998; 90: 1710-1719.
27. Inoue M, Tajima K, Takezaki T, Hamajima N, Hirose K, Ito H, et al. Epidemiology of pancreatic cancer in Japan: a nested case-control study from the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC). Int J Epidemiol 2003; 32: 257-262.
28. Ravindranath MH, Muthugounder S, Presser N, Viswanathan S. Anticancer therapeutic potential of soy isoflavone, genistein. Adv Exp Med Biol 2004; 546: 121-165.
29. Banerjee S, Zhang Y, Wang Z, Che M, Chiao PJ, Abbruzzese JL, et al. In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. Int J Cancer 2007; 120: 906-917.
30. Michael McClain R, Wolz E, Davidovich A, Bausch J. Genetic toxicity studies with genistein. Food Chem Toxicol 2006; 44: 42-55.
31. Shore S, Raraty MG, Ghaneh P, Neoptolemos JP. Review article: chemotherapy for pancreatic cancer. Aliment Pharmacol Ther 2003; 18: 1049-1069.
32. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-1806.
33. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002; 7 (Suppl 4): 2-8.